Lumanity and Parker Institute partner to support delivery of new immunotherapies
The alliance combines Lumanity’s commercial and development strategy capabilities with PICI’s translational research expertise
Read More
Tag: Parker Institute for Cancer Immunotherapy
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
